Skip to content
Search

Latest Stories

India’s ban on Rushdie’s Satanic Verses lifted due to missing order

India’s ban on Rushdie’s Satanic Verses lifted due to missing order

INDIA’s decades-long ban on the import of Salman Rushdie's controversial book The Satanic Verses has effectively been lifted after a court found the original notification imposing the ban could not be located.

The book by the India-born British author was banned in 1988, following complaints from some Muslim groups who viewed it as blasphemous. The Delhi high court reviewed a 2019 petition challenging the ban.


In its order on 5 November, the court noted that the Indian government was unable to produce any official record of the import ban. The court said it had "no other option except to presume that no such notification exists."

"The ban has been lifted as of 5 November because there is no notification," Uddyam Mukherjee, lawyer for petitioner Sandipan Khan, stated.

India's interior and finance ministries have not yet responded to requests for comment.

Khan had approached the court after being informed by bookstores that the novel could neither be sold nor imported in India. Unable to locate the official ban order on government websites, Khan turned to the court for clarification.

The court's 5 November order noted that none of the respondents could provide the notification, and even a customs department official who was reportedly involved in the drafting had “shown his helplessness” in producing it.

The Satanic Verses, Rushdie's fourth novel, stirred global controversy upon its release in September 1988, as some Muslims deemed its passages about Prophet Muhammad to be offensive.

The book’s publication led to violent protests and book burnings in various countries, including India, which has a large Muslim population.

In 1989, Iran’s then-supreme leader, Ayatollah Ruhollah Khomeini, issued a fatwa calling for Rushdie’s assassination, forcing the Booker Prize-winning author into hiding for several years.

In August 2022, Rushdie was attacked on stage in New York, leaving him blind in one eye and impairing the use of one hand.

(With inputs from Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less